Therefore, we were surprised to find that high levels of TEAD4 correlated with poor prognosis in ER+ breast cancer patients (Fig. 5a), which is in contrast to YAP (Fig. 1b), implying that TEAD may promote ER+ breast cancer progression. The gene discussed is TEAD4; the disease is breast cancer.